[Differences in antitumor effect of various BRMs by intratumoral administration: induction of immunosuppressive acidic protein].
The antitumor effects of biological response modifiers (BRM) in a new experimental mouse model, the "double grafted tumor system", were analysed. BALB/c mice received simultaneous inoculations of Meth-A fibrosarcoma cells on right flank (10(6) cells) and left flank (2 x 10(5) cells) on day 0, and BRMs were injected intratumorally into right tumor on day 3, 4 and 5. The growth of the left-flank tumor was the real target for the evaluation of a given drug after 21 days. PSK (a protein-bound polysaccharide preparation), IL-1 and Cepharanthin, cured not only the right, but also the left, non-treated tumor in a double grafted tumor system. OK-432 (a Streptococcus preparation) and BCG cured the right tumor and inhibited the growth of the left tumor. Lentinan (a polysaccharide preparation) inhibited neither the right nor the left tumor. Immunosuppressive acidic protein (IAP) in serum was increased transiently soon after intradermal injection of PSK, OK-432 and TNF in BALB/c mice. But Lentinan did not induce IAP. IAP in serum was gradually increased after intradermal inoculation of Meth-A tumor in BALB/c mice. At 21 days after tumor inoculation, IAP in serum reached a maximum level (300 micrograms/ml). The serum IAP level of Meth-A-bearing mice as well as that of normal mice increased after the intratumoral injection of PSK. At 21 days after tumor inoculation, IAP in PSK-treated mice returned to normal level. The biochemical differences between PSK-induced IAP (early, inflammatory IAP) and Meth-A-induced IAP (late, tumor-induced IAP) was investigated by crossed immunoaffino electrophoresis (CIAE). Inflammatory IAP was rich in biantennary sugar chain, and tumor-induced IAP was rich in tri-tetraantennary sugar chain.
Ebina
T
T
Division of Immunology, Research Institute, Miyagi Cancer Center.
Murata
K
K
D000818:Animals; D005354:Fibrosarcoma / Q000097:blood / Q000473:pathology / Q000628:therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D015552:Injections, Intralesional; D008264:Macrophages / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000097:blood; D009368:Neoplasm Transplantation; D010844:Picibanil / Q000627:therapeutic use; D011509:Proteoglycans / Q000627:therapeutic use*
D007155:Immunologic Factors; D009363:Neoplasm Proteins; D011509:Proteoglycans; C030193:immunosuppressive acidic protein; D010844:Picibanil; C010770:polysaccharide-K